FDA Sets July Meeting to Reconsider Peptide Compounding Limits Backed by RFK Jr.
1h
Developing
2
The Food and Drug Administration has formally scheduled an advisory committee meeting in July 2026 to weigh easing restrictions on more than seven injectable peptides, including influencer‑favored BPC‑157, after public advocacy from Robert F. Kennedy Jr. The agency says it will ask outside advisers whether those specific peptides should be added to the list of substances that pharmacies may legally compound and will, in the meantime, remove them from its restrictive “do not compound” list. Kennedy previewed the policy shift in a Joe Rogan interview, describing himself as a “big fan” of peptides, and the timing has drawn attention because the FDA’s compounding advisory panel currently has vacant seats that could be filled before the meeting.